GPT and colitis: The most frequent immune-related adverse events of grade 3 or 4 were diarrhoea (in 8% of patients in the combination group, 3% in the nivolumab group, and 4% in the ipilimumab group), colitis (in 7%, 1%, and 9%, respectively), and increased alanine aminotransferase (in 6%, 1%, and 1%, respectively).